Angelucci, E.; Artoni, A.; Fianchi, L.; Dovizio, M.; Iacolare, B.; Saragoni, S.; Esposti, L.D. Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med.2024, 13, 1342.
Angelucci, E.; Artoni, A.; Fianchi, L.; Dovizio, M.; Iacolare, B.; Saragoni, S.; Esposti, L.D. Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med. 2024, 13, 1342.
Angelucci, E.; Artoni, A.; Fianchi, L.; Dovizio, M.; Iacolare, B.; Saragoni, S.; Esposti, L.D. Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med.2024, 13, 1342.
Angelucci, E.; Artoni, A.; Fianchi, L.; Dovizio, M.; Iacolare, B.; Saragoni, S.; Esposti, L.D. Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med. 2024, 13, 1342.
Abstract
The therapeutic management of acquired thrombotic thrombocytopenic purpura (aTTP) has recently benefited from the introduction of caplacizumab, an agent directed to inhibition of platelet aggregation. This real-world analysis investigated the epidemiology, the demographic and clinical characteristics of aTTP patients in Italy before and after caplacizumab introduction in 2020. Hospitalized adults with aTTP were included using the administrative databases of healthcare entities covering 17 million residents. Epidemiological estimates of aTTP considered the 3-year period before and after caplacizumab introduction. After stratification by treatment or not with caplacizumab, aTTP patients were characterized for their demographic and clinical features. The annual incidence before and after 2020 was estimated in the range 4.3-5.8 cases/million and 3.6-4.6/million, respectively. From 2018 to 2022, 393 patients with aTTP were included, 42 of them treated with caplacizumab. Caplacizumab-treated patients were aged on average 46.8 years, 31% were males, and showed tendentially better clinical outcomes: no treated patients died at either 1 month or 3 months after caplacizumab treatment initiation, compared to 10.5% (1 month) and 11.1% (3 months) mortality among the untreated. Caplacizumab treatment was associated with a trend towards shorter hospital stays. These findings suggest that caplacizumab advent provided clinical and survival benefits for patients with aTTP.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
